Early kinetics of serum amyloid A predict clinical benefit to first-line chemoimmunotherapy and immunotherapy in advanced non-small cell lung cancer: a retrospective analysis

Abstract Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC), yet durable responses remain limited in a subset of patients. Serum amyloid A (SAA), an acute-phase protein linked to systemic inflammation, may reflect dynamic immu...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Du, Jianhua Zhan, Kai Wu, Yanming Wang, Li Zhang, Shaodong Hong
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Biomarker Research
Subjects:
Online Access:https://doi.org/10.1186/s40364-025-00791-1
Tags: Add Tag
No Tags, Be the first to tag this record!